Stockscreener 앱 받기
0.48%
전일 마감가:
$24.94
열려 있는:
$24.87
하루 거래량:
3.05M
Relative Volume:
0.09
시가총액:
$140.91B
수익:
$59.37B
순이익/손실:
$4.25B
주가수익비율:
13.55
EPS:
1.83
순현금흐름:
$8.23B
1주 성능:
-4.61%
1개월 성능:
-14.21%
6개월 성능:
-13.10%
1년 성능:
-18.09%
1일 변동 폭
$24.77
$24.90
1주일 범위
$24.48
$25.70
52주 변동 폭
$24.48
$31.54
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| PFE | 24.79 | 140.91B | 59.37B | 4.25B | 8.23B | 1.83 |
| LLY | 741.47 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 102.50 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 153.15 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 167.50 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 97.14 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Is Pfizer Stock A Sell With Vaccine Skeptic Robert F. Kennedy Jr. Tapped To Lead HHS? - Yahoo! Voices
Pfizer Inc. (NYSE:PFE) Shares Acquired by America First Investment Advisors LLC - MarketBeat
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU - Zacks Investment Research
Pfizer Inc. (NYSE:PFE) Shares Sold by Intech Investment Management LLC - MarketBeat
The Escalator: Pfizer, Eli Lilly, CVS Health and more - MM+M Online
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam) - BioSpace
Ontario Teachers Pension Plan Board Has $1.12 Million Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer elevates Chris Boshoff to top R&D role - pharmaphorum
Mitochondrial-Based Therapeutics Market Key Players Analysis - openPR
Zai Lab Partners with Pfizer to Commercialize Novel Antibiotic XACDURO in China | ZLAB Stock News - StockTitan
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia - Pharmaceutical Technology
Pfizer, Flynn Still Face Fines Over Epilepsy Drug Sale To NHS - Law360
Meta, Pfizer on DOL List of Upcoming Contractor Anti-Bias Audits - Bloomberg Law
Health Care Climbs as Obesity-Drug Makers ReboundHealth Care Roundup - Marketscreener.com
How Pfizer is trying to make U.S. healthcare easier to navigate - Fast Company
Pfizer Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Pfizer Picks Boshoff To Head R&D, A Smooth Transition In An Uncertain Time - Citeline News & Insights
Pfizer (NYSE:PFE) Stock Price Down 0.6%Should You Sell? - MarketBeat
EC approval for Pfizer’s Hympavzi - The Pharma Letter
Pfizer promoted oncology chief Chris Boshoff to serve as CSO, R&D president - MM+M Online
Flagship reveals new agreements under Pfizer link-up - The Pharma Letter
Pzena Investment Management LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer, under pressure to change, names oncology head as new R&D chief - BioPharma Dive
Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief - GuruFocus.com
Pfizer names oncology head Chris Boshoff as R&D chief - Reuters
Pfizer Taps Cancer Chief to Lead Research, Find Hit Drugs - MSN
Pfizer Names New Chief Scientific Officer And President Of R&D - Contract Pharma
Company veteran named chief scientific officer at Pfizer - ShareCast
Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO - BioSpace
Chris Boshoff takes on new role at Pfizer - The Pharma Letter
First Horizon Advisors Inc. Purchases 95,749 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer: Marketing authorization for Hympavzi in the EU - Marketscreener.com
Pfizer promotes oncology chief to lead R&D as activist Starboard circles - Financial Times
Pfizer: new Chief Scientific Officer on January 1 - Marketscreener.com
Pfizer bags EU okay for haemophilia drug Hympavzi - pharmaphorum
Pfizer names Chris Boshoff as new R&D chief starting 2025 - Investing.com
Pfizer names head of oncology as new R&D chief - Seeking Alpha
Pfizer names new chief scientific officer - baha news
Pfizer taps insider as chief science officer amid pressure from activist Starboard - MarketWatch
Pfizer Names New R&D Chief: Dr. Boshoff to Lead Scientific Innovation After 24 Drug Approvals | PFE Stock News - StockTitan
Flagship, Pfizer alliance yields two more startup deals - BioPharma Dive
Pfizer names Chris Boshoff as new R&D chief, WSJ reports - Marketscreener.com
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer - PR Newswire
Pfizer Names New R&D Chief - Yahoo! Voices
Is It Time to Sell Eli Lilly and Pfizer Stocks? - Yahoo! Voices
Pfizer's HYMPAVZI Wins EU Approval: First Weekly Treatment for Severe Hemophilia | PFE Stock News - StockTitan
StockNews.com Downgrades Pfizer (NYSE:PFE) to Buy - MarketBeat
Penicillin Drug Market: Comprehensive Analysis and Key Players-Pfizer, Inc., Novartis AG, Sanofi S.A - openPR
UK Patent Win Over GSK Boosts Pfizer in Global RSV Vaccine Fight - BioSpace
Pfizer Unit Can't Get $75M Left In Insider Trading Deal Fund - Law360
Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules - Reuters
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.09%
1.40%
자본화:
|
볼륨(24시간):